Search

Now showing items 1-10 of 44

Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis

Younossi, ZM; Stepanova, M; Feld, J; Zeuzem, S; Sulkowski, M; Foster, GR; Mangia, A; Charlton, M; O'Leary, JG; Curry, MP;... (2017-03)

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Jacobson, IM; Lawitz, E; Gane, EJ; Willems, BE; Ruane, PJ; Nahass, RG; Borgia, SM; Shafran, SD; Workowski, KA; Pearlman, B;... (2017-07)

Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity

De Silva, S; Li, W; Kemos, P; Brindley, JH; Feakins, R; Chinaleong, J; Samsuddin, S; Foster, GR; Syn, WK; Alazawi, W (2017)

Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?

Bridge, SH; Pagano, S; Jones, M; Foster, GR; Neely, D; Vuilleumier, N; Bassendine, MF (2018-01)

BACKGROUND/PURPOSE: One to three per cent of the world's population has hepatitis C virus (HCV) infection, which is not only a major cause of liver disease and cancer but also associated with an increased risk of ...

Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".

da Silva Filipe, A; Sreenu, V; Hughes, J; Aranday-Cortes, E; Irving, WL; Foster, GR; Agarwal, K; Rosenberg, W; Macdonald, D; Richardson, P;... (2018-01-12)

C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks

Foster, GR; Agarwal, K; Cramp, M; Moreea, S; Barclay, ST; Collier, J; Brown, AS; Ryder, SD; Ustianowski, A; Forton, DM;... (2016-10)

Decreased health resource utilization by peri-transplant (PT) HCV patients after successful direct acting antiviral (DAA) therapy

Verma, S; Foster, GR; Sadler, MD; Heneghan, MA; Irving, W; Considine, AB; Childs, K; Suddle, A; Carey, I; Agarwal, K (2016-10)

Gender Differences in Patients Treated for HCV: Efficacy and Safety of Sofosbuvir/Velpatasvir in Women

Tran, TT; Feld, JJ; Foster, GR; Naik, S; Eggleton, ES; Zhang, J; Natha, M; Llewellyn, J; Kreter, B; Brainard, DM;... (2016-10)

Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin

Agarwal, K; Schultz, M; Pianko, S; Bank, L; Collier, J; George, J; Priest, M; Ryder, SD; Burman, BE; Cheent, K;... (2016-10)

Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics

Younossi, ZM; Stepanova, M; Feld, JJ; Zeuzem, S; Sulkowski, MS; Foster, GR; Mangia, A; Charlton, MR; O'Leary, JG; Curry, MP;... (2016-10)

1
2
3
4
. . .
5